Typewriter Therapeutics raises $56M Series A to build RNA-based jumping-gene therapies for in vivo CAR-T and genetic liver disease.
Typewriter CEO Matthew Stanton (L) and CSO Leanne Peiser
September 2, 2026 07:00 AM EDT
FinancingStartupsCell/Gene Tx
Exclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T
Ryan Cross
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a…
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go…
ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies
